Wall Street analyst estimates for HCW Biologics Inc. (HCWB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-1.08 | ||
| 2026-08-14 | $-11.58 | $-1.98 | -484.8% |
| 2026-05-14 | $2.22 | $-2.64 | +184.1% |
| 2026-03-31 | $-15.78 | $-5.04 | -213.1% |
| 2025-11-14 | $-12.12 | $9.48 | -227.8% |
| 2025-08-18 | $-40.73 | $10.80 | -477.1% |
| 2025-05-15 | $-0.30 | ||
| 2025-03-28 | $-19.20 | $21.60 | -188.9% |
Valuation Ratios
| Price / Book | 0.08 |
| EV / EBITDA | -1.60 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | $4.1M | 0 | $6.7M | $2.8M | $2.6M | $54232 |
| Cost of Revenue | $421817 | 0 | 0 | $4.1M | $2.3M | $1.6M | $43386 |
| Gross Profit | -$421817 | $4.1M | 0 | $2.6M | $560360 | $959403 | $10846 |
| Research & Development | $5.1M | $7.3M | $8.2M | $9.3M | $7.7M | $6.4M | $5.4M |
| Selling, General & Admin | $1.8M | $2.4M | $5.3M | $8.0M | $13.1M | $21.9M | $7.7M |
| Operating Expenses | $6.9M | $9.9M | $13.4M | $17.7M | $26.3M | $30.4M | $11.3M |
| Operating Income | -$7.4M | -$5.8M | -$13.4M | -$15.1M | -$25.7M | -$29.5M | -$11.3M |
| EBITDA | -$6.9M | -$5.3M | -$12.3M | -$14.1M | -$23.6M | -$27.7M | -$5.7M |
| Interest Expense | 0 | 0 | 0 | $126660 | $283042 | $1.2M | $1.3M |
| Pre-tax Income | -$7.3M | -$5.8M | -$12.9M | -$14.9M | -$25.0M | -$30.0M | -$8.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$7.3M | -$5.8M | -$12.9M | -$14.9M | -$25.0M | -$30.0M | -$8.0M |
| EPS | $-1.26 | $-0.96 | $-2.16 | $-2.52 | $-4.20 | $-4.62 | $-63.78 |
| EPS (Diluted) | $-1.26 | $-0.96 | $-2.16 | $-2.52 | $-4.20 | $-4.62 | $-63.78 |
| Shares Outstanding (Diluted) | $6.1M | $6.1M | $6.0M | $6.0M | $6.0M | $6.5M | $349617 |
Price
| Price | $2.01 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · BCLI · CELZ
Explore sector: Healthcare · Biotechnology
More sections of HCWB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks